Kolon Life Science Inc. (KOSDAQ:102940)

Market Cap	214.42B -46.2%
Revenue (ttm)	213.81B +27.5%
Net Income	35.33B
EPS	2,498.04
Shares Out	13.09M
PE Ratio	6.56
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	233,417
Open	15,800
Previous Close	15,600
Day's Range	15,730 - 16,980
52-Week Range	13,210 - 72,700
Beta	0.20
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Kolon Life Science

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ...

• Industry: Chemicals
• Sector: Materials
• Founded: 2000
• Employees: 425
• Stock Exchange: KOSDAQ
• Ticker Symbol: 102940

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 10, 2026

Data Sources Report a data error